A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage
ASCO 2006 - Summary Coverage
Date: June 2-6, 2006
Location: Atlanta, Georgia

The content presented here was prepared by independent authors under the editorial supervision of OncoEd and is not endorsed or sanctioned by the 42nd Annual Meeting of the American Society of Clinical Oncology.
ASCO 2006 Conference Summaries
ASCO 2006
Date: June 2-6, 2006
Location: Atlanta, Georgia
Author:

Pre-Clinical and Clinical Issues Regarding Head and Neck Cancer CME 

Advances in the Treatment of Prostate Cancer: Update from ASCO 2006

Advances in the Treatment of Renal Cell Carcinoma: Update from ASCO 2006

Developments in the Treatment of Follicular Non-Hodgkin's Lymphoma (NHL): Update from ASCO 2006 and ASH 2005

Emerging Therapies for Non-Hodgkin's Lymphoma (NHL): Update from ASCO 2006 and ASH 2005

Developments in the Treatment of Chronic Lymphocytic Leukemia (CLL): A Brief Update from ASCO 2006

Update in the Management of Non-Small Cell Lung Cancer (NSCLC): ASCO 2006

Advances in the Management of Neutropenia and Anemia: ASCO 2006

ASCO 2006: Update on the Management of Colorectal Cancer (CRC)

ASCO 2006: Advances in the Treatment of Chronic Lymphocytic Leukemia (CLL)

ASCO 2006: Update of Studies in Chronic Myeloid Leukemia (CML)

ASCO 2006: Update of Studies in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

ASCO 2006 News Stories
More Evidence that Vitamin D Reduces Risk of Cancer in Women (6/11/2007)

Gemzar® Combined with Eloxatin® or Platinol® Improves Survival for Patients with Advanced Pancreatic Cancer (7/16/2006)

Avastin®/Tarceva® Effective Alternative to Chemotherapy in Recurrent Non-Small Cell Lung Cancer (7/10/2006)

Velcade® Plus Gemzar®/Paraplatin® Highly Active in Advanced NSCLC (7/10/2006)

Lapatinib Superior to Hormonal Therapy in Patients with Renal Cell Carcinoma Failing Initial Therapy (7/6/2006)

2007 Conferences



© 1998-2007 CancerConsultants.com  All Rights Reserved.